Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Tumor Response Rate 1Hepatic Malignancies 1Carcinoma, Hepatocellular 1

Interventions

Radiosurgery 24lenvatinib 19Radiofrequency Ablation 16Hepatectomy 13Sorafenib 12Surgical Procedures, Operative 9Radiotherapy 9camrelizumab 7Magnetic Resonance Spectroscopy 7Blood Specimen Collection 7Bevacizumab 7sintilimab 6apatinib 6Immune Checkpoint Inhibitors 6Electroporation 6atezolizumab 5tislelizumab 4Yttrium-90 4Proton Therapy 4Oxaliplatin 4Liver Transplantation 4Doxorubicin 4Control Groups 4Cisplatin 4Chemoembolization, Therapeutic 4Catheter Ablation 4spartalizumab 3entecavir 3X-Rays 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Carcinoma, Hepatocellular × Sirtuins × Clear all
NCT05994859 2023-09-14

SIRT for Potentially Resectable HCC

Second Affiliated Hospital of Guangzhou Medical University

Phase NA Recruiting
35 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡